HCQ, povidone-iodine throat spray touted for COVID-19 prophylaxis
22 Apr 2021
byJairia Dela Cruz
Short-term use of either oral hydroxychloroquine (HCQ) and povidone-iodine throat spray have shown a signal of reducing the incidence of SARS-CoV-2 infection among young men living in a closed and high-exposure setting, with either compound being superior to oral vitamin C, as shown in an open-label trial from Singapore.
HCQ, povidone-iodine throat spray touted for COVID-19 prophylaxis
22 Apr 2021